Ranking of the 2nd-look transurethral electroresection of the superficial carcinoma of the bladder;Die wertigkeit der 2nd look transurethralen elektroresektion beim oberflächlichen blasenkarzinom

Aktuelle Urologie

Volumn 32, Issue 4, 2001, Pages 173-177

  Engelhardt, P F ^a,b   Simak, R ^a   Daha, L K ^a   Plas, E ^a   Pfluger H ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Urologische Universitatsklinik   (Austria)

Author keywords

Residual cancer; Superficial bladder cancer; Transurethral resection

Indexed keywords

EID: 0035595258     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15848     Document Type: Article

References (20)

1. Cutler SJ, Heney NM, Friedell GH. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: Bonney WW and Prout GR (eds.), Bladder Cancer, AUA Monographs, Vol. 1, Chapter 4,. Baltimore: William and Wilkins, 1982: 35-46
2. Heney NM, Ahmed S, Flanagan MJ. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083-1086
3. Mufti GR, Virdi JS, Singh M. Solitary Ta-T1 G1 bladder tumour - history and long-term prognosis. Eur Urol 1990; 18: 101-106
4. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162: 74-76
5. Flamm J. Rezidivrisiko und topische Prophylaxe bei primärem oberflächlichem Harnblasenkarzinom. Acta Chir Austr (Suppl) 1988; 77: 1-30
6. Huland H, Otto U, Droese M, Klöppel G. Long-term mitomycin c instillation after transurethral resection of superficial bladder carcinoma - influence on recurrence, progression and survival. J Urol 1984; 132: 27-29
7. Flamm J, Steiner R. Stellenwert der differenzierten transurethralen Resektion beim primären oberflächlichen Harnblasenkarzinom. Urologe A 1991; 30: 111-113
8. Brausi M, Kurth K, van der Meijden AP, Sylvester RJ, Collette L. Variability in the 3-month recurrence rate after TUR in superficial transitional cell carcinoma of the bladder: a combined analysis of 8 EORTC studies. J Urol 1998; 159S: 143 (541A)
9. nd TUR. J Urol 1998; 159S: 143 (543A)
10. nd TUR for superficial bladder cancer: a must? J Urol 1998; 159S: 143 (542A)
11. Riedl C, Plas E, Pflüger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid (submitted).
12. Abel PD. Follow-up of patients with superficial transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993; 72: 135-142
13. RUTT (Registry for Urinary Tract Tumors). Jahresbericht. Verh Dtsch Ges Urol 1985; 37: 665
14. Holmäng S, Hedelin H, Anderström C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823-1827
15. Whitmore WF. Toward the rational management of bladder cancer: an overview. Urology (Supplement) 1988; 31, No 2: 5-8
16. Bishop MC. The dangers of a long urological waiting list. Br J Urol 1990; 65: 433-440
17. Gulliford M, Petruckevitch A, Burney P. Survival with bladder cancer: association of treatment delay, type of surgeon and modality of treatment. Br Med J 1991; 303: 437-440
18. Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM and the members of the Dutch South-East Cooperative Urological Group. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Br J Urol 1994; 73: 164-171
19. Simak R, Wiener H, Foeger A, Susani M, Zhang Z-F, Maier U, Marberger M. Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy. Eur Urol 1996; 29: 391-398
20. Kurth KH, Bouffioux C, Sylvester R, van der Meijden APM, Oosterlinck W, Brausi M. Treatment of Superficial Bladder Tumors: Achievements and Needs. Eur Urol 2000; 37 (suppl 3): 1-9